Humoral cross-reactivity between Zika and dengue viruses: Implications for protection and pathology

Emerging Microbes and Infections

Volumn 6, Issue 5, 2017, Pages

  Priyamvada, Lalita ^a   Hudson, William ^a   Ahmed, Rafi ^a   Wrammert, Jens ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antibody dependent enhancement; Cross protection; Cross reactive antibodies; DENV; ZIKV

Indexed keywords

CROSS REACTING ANTIBODY; NEUTRALIZING ANTIBODY; VIRUS GLYCOPROTEIN; GLYCOPROTEIN E, FLAVIVIRUS; VIRUS ANTIBODY; VIRUS ENVELOPE PROTEIN;

ANTIBODY DEPENDENT ENHANCEMENT; ANTIBODY RESPONSE; CLINICAL FEATURE; CROSS REACTION; DENGUE VIRUS; GENETICS; HUMAN; HUMORAL IMMUNITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; VIRUS ENTRY; ZIKA VIRUS; ANIMAL; CARIBBEAN; CHEMISTRY; CROSS PROTECTION; DENGUE; IMMUNOLOGY; MOSQUITO; MOUSE; PATHOPHYSIOLOGY; SOUTH AMERICA; VIROLOGY; ZIKA FEVER;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIBODY-DEPENDENT ENHANCEMENT; CARIBBEAN REGION; CROSS PROTECTION; CROSS REACTIONS; CULICIDAE; DENGUE; DENGUE VIRUS; HUMANS; IMMUNITY, HUMORAL; MICE; SOUTH AMERICA; VIRAL ENVELOPE PROTEINS; ZIKA VIRUS; ZIKA VIRUS INFECTION;

EID: 85029660448     PISSN: None     EISSN: 22221751     Source Type: Journal    
DOI: 10.1038/emi.2017.42     Document Type: Review

References (71)

1. Dick GW, Kitchen SF, Haddow AJ. Zika virus. I. Isolations and serological specificity. Trans R Soc Trop Med Hyg 1952; 46: 509-520.
2. Dick GW. Zika virus. II. Pathogenicity and physical properties. Trans R Soc Trop Med Hyg 1952; 46: 521-534.
3. Simpson DI. Zika virus infection in man. Trans R Soc Trop Med Hyg 1964; 58: 335-338.
4. Moore DL, Causey OR, Carey DE et al. Arthropod-borne viral infections of man in Nigeria, 1964-1970. Ann Trop Med Parasitol 1975; 69: 49-64.
5. Fagbami AH. Zika virus infections in Nigeria: virological and seroepidemiological investigations in Oyo State. J Hyg (Lond) 1979; 83: 213-219.
6. Olson JG, Ksiazek TG, Suhandiman, Triwibowo. Zika virus, a cause of fever in Central Java, Indonesia. Trans R Soc Trop Med Hyg 1981; 75: 389-393.
7. Musso D, Gubler DJ. Zika virus. Clin Microbiol Rev 2016; 29: 487-524.
8. Wikan N, Smith DR. Zika virus: history of a newly emerging arbovirus. Lancet Infect Dis 2016; 16: e119-e126.
9. Duffy MR, Chen TH, Hancock WT et al. Zika virus outbreak on Yap Island, Federated States of Micronesia. N Engl J Med 2009; 360: 2536-2543.
10. Lanciotti RS, Kosoy OL, Laven JJ et al. Genetic and serologic properties of Zika virus associated with an epidemic, Yap State, Micronesia, 2007. Emerg Infect Dis 2008; 14: 1232-1239.
11. Cao-Lormeau VM, Roche C, Teissier A et al. Zika virus, French polynesia, South Pacific, 2013. Emerg Infect Dis 2014; 20: 1085-1086.
12. Roth A, Mercier A, Lepers C et al. Concurrent outbreaks of dengue, chikungunya and Zika virus infections - an unprecedented epidemic wave of mosquito-borne viruses in the Pacific 2012-2014. Euro Surveill 2014; 19: 20929.
13. Oehler E, Watrin L, Larre P et al. Zika virus infection complicated by Guillain-Barre syndrome-case report, French Polynesia, December 2013. Euro Surveill 2014; 19: 20720.
14. Cao-Lormeau VM, Blake A, Mons S et al. Guillain-Barre Syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study. Lancet 2016; 387: 531-1539.
15. Campos GS, Bandeira AC, Sardi SI. Zika virus outbreak, Bahia, Brazil. Emerg Infect Dis 2015; 21: 1885-1886.
16. Zanluca C, Melo VC, Mosimann AL, Santos GI, Santos CN, Luz K. First report of autochthonous transmission of Zika virus in Brazil. Mem Inst Oswaldo Cruz 2015; 110: 569-572.
17. Cardoso CW, Paploski IA, Kikuti M et al. Outbreak of exanthematous illness associated with Zika, chikungunya, and dengue viruses, Salvador, Brazil. Emerg Infect Dis 2015; 21: 2274-2276.
18. PAHO/WHO. Regional Zika epidemiological update (Americas) March 10 2017. Washington, DC: PAHO/WHO, 2016. Available at http://www.paho.org/hq/index.php? option=com-docman&task=doc-view&Itemid=270&gid=38610&lang=en. (accessed 21 March 2017).
19. Likos A, Griffin I, Bingham AM et al. Local mosquito-borne transmission of Zika virus - Miami-Dade and Broward Counties, Florida. 2016MMWR Morb Mortal Wkly Rep 2016; 65: 1032-1038.
20. de Paula Freitas B, de Oliveira Dias JR, Prazeres J et al. Ocular findings in infants with microcephaly associated with presumed Zika virus congenital infection in Salvador, Brazil. JAMA Ophthalmol 2016; 134: 529-535.
21. Mlakar J, Korva M, Tul N et al. Zika virus associated with microcephaly. N Engl J Med 2016; 374: 951-958.
22. Ventura CV, Maia M, Bravo-Filho V, Gois AL, Belfort R Jr. Zika virus in Brazil and macular atrophy in a child with microcephaly. Lancet 2016; 387: 228.
23. Kleber de Oliveira W, Cortez-Escalante J, De Oliveira WT et al. Increase in reported prevalence of microcephaly in infants born to women living in areas with confirmed Zika virus transmission during the first trimester of pregnancy - Brazil, 2015. MMWR Morb Mortal Wkly Rep 2016; 65: 242-247.
24. Martines RB, Bhatnagar J, Keating MK et al. Notes from the field: evidence of Zika virus infection in brain and placental tissues from two congenitally infected newborns and two fetal losses-Brazil, 2015. MMWR Morb Mortal Wkly Rep 2016; 65: 159-160.
25. Driggers RW, Ho CY, Korhonen EM et al. Zika virus infection with prolonged maternal viremia and fetal brain abnormalities. N Engl J Med 2016; 374: 2142-2151.
26. Calvet G, Aguiar RS, Melo AS et al. Detection and sequencing of Zika virus from amniotic fluid of fetuses with microcephaly in Brazil: a case study. Lancet Infect Dis 2016; 16: 653-660.
27. Rasmussen SA, Jamieson DJ, Honein MA, Petersen LR. Zika virus and birth defects - reviewing the evidence for causality. N Engl J Med 2016; 374: 1981-1987.
28. Bhatt S, Gething PW, Brady OJ et al. The global distribution and burden of dengue. Nature 2013; 496: 504-507.
29. Stanaway JD, Shepard DS, Undurraga EA et al. The global burden of dengue: an analysis from the Global Burden of Disease Study 2013. Lancet Infect Dis 2016; 16: 712-723.
30. Sirohi D, Chen Z, Sun L et al. The 3.8A resolution cryo-EM structure of Zika virus. Science 2016; 352: 467-470.
31. Prasad VM, Miller AS, Klose T et al. Structure of the immature Zika virus at 9A resolution. Nat Struct Mol Biol 2017; 24: 184-186.
32. Priyamvada L, Quicke KM, Hudson WH et al. Human antibody responses after dengue virus infection are highly cross-reactive to Zika virus. Proc Natl Acad Sci USA 2016; 113: 7852-7857.
33. Stettler K, Beltramello M, Espinosa DA et al. Specificity, cross-reactivity, and function of antibodies elicited by Zika virus infection. Science 2016; 353: 823-826.
34. Ye Q, Liu ZY, Han JF, Jiang T, Li XF, Qin CF. Genomic characterization and phylogenetic analysis of Zika virus circulating in the Americas. Infect Genet Evol 2016; 43: 43-49.
35. Dai L, Song J, Lu X et al. Structures of the Zika virus envelope protein and its complex with a flavivirus broadly protective antibody. Cell Host Microbe 2016; 19: 696-704.
36. Sukupolvi-Petty S, Austin SK, Purtha WE et al. Type- and subcomplex-specific neutralizing antibodies against domain III of dengue virus type 2 envelope protein recognize adjacent epitopes. J Virol 2007; 81: 12816-12826.
37. Shrestha B, Brien JD, Sukupolvi-Petty S et al. The development of therapeutic antibodies that neutralize homologous and heterologous genotypes of dengue virus type 1. PLoS Pathog 2010; 6: e1000823.
38. Wahala WM, Kraus AA, Haymore LB, Accavitti-Loper MA, de Silva MA. Dengue virus neutralization by human immune sera: role of envelope protein domain III-reactive antibody. Virology 2009; 392: 103-113.
39. Midgley CM, Bajwa-Joseph M, Vasanawathana S et al. An in-depth analysis of original antigenic sin in dengue virus infection. J Virol 2011; 85: 410-421.
40. Dejnirattisai W, Wongwiwat W, Supasa S et al. A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus. Nat Immunol 2015; 16: 170-177.
41. de Alwis R, Smith SA, Olivarez NP et al. Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions. Proc Natl Acad Sci USA 2012; 109: 7439-7444.
42. Teoh EP, Kukkaro P, Teo EW et al. The structural basis for serotype-specific neutralization of dengue virus by a human antibody. Sci Transl Med 2012; 4: 139ra183.
43. Fibriansah G, Tan JL, Smith SA et al. A highly potent human antibody neutralizes dengue virus serotype 3 by binding across three surface proteins. Nat Commun 2015; 6: 6341.
44. Fibriansah G, Ibarra KD, Ng TS et al. Dengue virus. Cryo-EM structure of an antibody that neutralizes dengue virus type 2 by locking E protein dimers. Science 2015; 349: 88-91.
45. Wang Q, Yang H, Liu X et al. Molecular determinants of human neutralizing antibodies isolated from a patient infected with Zika virus. Sci Transl Med 2016; 8: 369ra179.
46. Sapparapu G, Fernandez E, Kose N et al. Neutralizing human antibodies prevent Zika virus replication and fetal disease in mice. Nature 2016; 540: 443-447.
47. Swanstrom JA, Plante JA, Plante KS et al. Dengue virus envelope dimer epitope monoclonal antibodies isolated from dengue patients are protective against Zika VIrus. MBio 2016; 7: e01123-16.
48. Dejnirattisai W, Supasa P, Wongwiwat W et al. Dengue virus sero-cross-reactivity drives antibody-dependent enhancement of infection with zika virus. Nat Immunol 2016; 17: 1102-1108.
49. Durand MA, Bel M, Ruwey I, Marfel M, Yug L, Ngaden V. An outbreak of dengue fever in Yap State. Pac Health Dialog 2005; 12: 99-102.
50. Cao-Lormeau VM, Roche C, Aubry M et al. Recent emergence of dengue virus serotype 4 in French Polynesia results from multiple introductions from other South Pacific Islands. PLoS One 2011; 6: e29555.
51. Cao-Lormeau VM, Musso D. Emerging arboviruses in the Pacific. Lancet 2014; 384: 1571-1572.
52. Singh N, Kiedrzynski T, Lepers C, Benyon EK. Dengue in the Pacific-an update of the current situation. Pac Health Dialog 2005; 12: 111-119.
53. Aubry M, Finke J, Teissier A et al. Seroprevalence of arboviruses among blood donors in French Polynesia, 2011-2013. Int J Infect Dis 2015; 41: 11-12.
54. Beltramello M, Williams KL, Simmons CP et al. The human immune response to Dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity. Cell Host Microbe 2010; 8: 271-283.
55. Vaughan K, Greenbaum J, Blythe M, Peters B, Sette A. Meta-analysis of all immune epitope data in the Flavivirus genus: inventory of current immune epitope data status in the context of virus immunity and immunopathology. Viral Immunol 2010; 23: 259-284.
56. Smith SA, Zhou Y, Olivarez NP, Broadwater AH, de Silva AM, Crowe JE Jr. Persistence of circulating memory B cell clones with potential for dengue virus disease enhancement for decades following infection. J Virol 2012; 86: 2665-2675.
57. Friberg H, Jaiswal S, West K, O'Ketch M, Rothman AL, Mathew A. Analysis of human monoclonal antibodies generated by dengue virus-specific memory B cells. Viral Immunol 2012; 25: 348-359.
58. Dejnirattisai W, Jumnainsong A, Onsirisakul N et al. Cross-reacting antibodies enhance dengue virus infection in humans. Science 2010; 328: 745-748.
59. Xu M, Hadinoto V, Appanna R et al. Plasmablasts generated during repeated dengue infection are virus glycoprotein-specific and bind to multiple virus serotypes. J Immunol 2012; 189: 5877-5885.
60. Priyamvada L, Cho A, Onlamoon N et al. B cell responses during secondary dengue infection are dominated by highly cross-reactive, memory-derived plasmablasts. J Virol 2016; 90: 5574-5585.
61. Barba-Spaeth G, Dejnirattisai W, Rouvinski A et al. Structural basis of potent Zikadengue virus antibody cross-neutralization. Nature 2016; 536: 48-53.
62. Halstead SB. Neutralization and antibody-dependent enhancement of dengue viruses. Adv Virus Res 2003; 60: 421-467.
63. Vaughn DW, Green S, Kalayanarooj S et al. Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. J Infect Dis 2000; 181: 2-9.
64. Kliks SC, Nisalak A, Brandt WE, Wahl L, Burke DS. Antibody-dependent enhancement of dengue virus growth in human monocytes as a risk factor for dengue hemorrhagic fever. Am J Trop Med Hyg 1989; 40: 444-451.
65. Zhao H, Fernandez E, Dowd KA et al. Structural basis of Zika virus-specific antibody protection. Cell 2016; 166: 1016-1027.
66. PAHO/WHO. Zika cases and congenital syndrome associated with Zika virus reported by countries and terriroties in the Americas, 2015-2016 Cumulative cases. Washington, DC: PAHO/WHO, 2016. Available at http://www.paho.org/hq/index.php?option=com-docman& task=doc-view&Itemid=270&gid=37582&lang=en (accessed 21 March 2017).
67. Kumar S, Stecher G, Tamura K. MEGA7: molecular evolutionary genetics analysis version 7.0 for bigger datasets. Mol Biol Evol 2016; 33: 1870-1874.
68. Jones DT, Taylor WR, Thornton JM. The rapid generation of mutation data matrices from protein sequences. Comput Appl Biosci 1992; 8: 275-282.
69. Wickham H. ggplot2: Elegant Graphics For Data Analysis. New York: Springer, 2009.
70. Kearse M, Moir R, Wilson A et al. Geneious basic: an integrated and extendable desktop software platform for the organization and analysis of sequence data. Bioinformatics 2012; 28: 1647-1649.
71. Rouvinski A, Guardado-Calvo P, Barba-Spaeth G et al. Recognition determinants of broadly neutralizing human antibodies against dengue viruses. Nature 2015; 520: 109-113.